

JUL. 24. 2006 4:14PM

BMS PATENT DEPT

NO. 6862 P. 1



Bristol-Myers Squibb Company

Worldwide Medicines Group
P.O. Box 4000 Princeton, NJ 08543-4000

RECEIVED
CENTRAL FAX CENTER

JUL 24 2006

DATE: July 24, 2006

FACSIMILE TRANSMITTAL COVER SHEET

URGENT

TO: USPTO

FAX: 1-571-273-8300

OF PAGES: 3 (INCLUDING FAX TRANSMITTAL SHEET)

FROM: Sammy G. Duncan, Jr.

FAX #: (609) 252-4526

PHONE #: (609) 252-6270

RE: U.S. Appln. Serial No.: 10/764,118
Attorney Docket No. : LA0108 NP

Comments: Please see attached:

1. Response to Restriction Requirement

Should you not receive all the pages of this facsimile, please contact Nell Bartholomew at 609-252-6925

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

JUL. 24. 2006 4:14PM

BMS PATENT DEPT

NO. 6862 P. 2

RECEIVED
CENTRAL FAX CENTER

JUL 24 2006

LA0108 NP

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Sammy G. Duncan, Jr.
Type or print name

Signature

July 24, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
WILLIAM WASHBURN, ET AL
APPLICATION NO: 10/764118
FILED: 01/23/2004
FOR: CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR
THE THYROID RECEPTOR

ART UNIT: 1614
EXAMINER: GOLAM M. M. SHAMEEM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

COMMUNICATION

In response to the Restriction Requirement mailed June 22, 2006, in connection with the above-identified application. Applicants request entry of the following remarks

REMARKS


Responsive to the Restriction Requirement dated June 22, 2006, Applicants elect, with traverse, Group I "drawn to a compound of formula I classified in class 548 and numerous subclasses." (June 22, 2006 Restriction Requirement, page 2).

Applicants respectfully traverse the requirement for an Election on the grounds that the reasons stated by the Examiner do not support his contention that each of the five groups are independent and distinct. Applicants do not believe that a serious burden would be imposed upon the Examiner to search the Applicants' claims.

As required in the June 22, 2006 Restriction Requirement, Applicants hereby elect Example 1 (Page 1, line 8) in the specification as originally filed.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Sammy G. Duncan, Jr., Ph.D.
Attorney for Applicant
Reg. No. 46,675
Phone: 609-252-6270
Date: July 24, 2006